Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Newton Golf Company FY2025 Earnings Call - Record Revenue Growth, But Cash Runway Tight
Newton Golf posted a startling top-line sprint in FY2025, with revenue up 136% to $8.1 million driven by a 157% surge in direct-to-consumer sales and broad adoption of its Newton Motion shaft platform...
- Revenue jumped 136% year over year to $8.1 million in FY2025, a new company record.
- Direct-to-consumer sales drove most of the gain, rising 157% to $7.4 million.
- Newton Motion shaft platform showed strong traction, with Fast Motion launched in 2025 becoming the company’s best-selling product.
- +13 more takeaways
Knightscope Q4 2025 Earnings Call - Event Risk acquisition recasts Knightscope as a managed-service play to scale into a $230B TAM
Knightscope closed 2025 with modest revenue growth, widening losses, and a cash cushion reset by financings, while announcing a strategic pivot. The company bought Event Risk to combine human guarding...
- Strategic pivot: Knightscope acquired Event Risk and intends to sell an integrated managed service combining human guards, robotics, and software, reframing the company as an Autonomous Security Force and a managed service provider.
- TAM remains $230 billion as presented on knightscope.com/america, management says the acquisition accelerates ability to penetrate that market rather than changing the TAM itself.
- Q4 2025 revenue declined ~9.8% year-over-year, driven largely by supply-chain constraints that delayed ECD product deliveries; services revenue was largely unchanged in the quarter.
- +12 more takeaways
American Shared Hospital Services Q4 2025 Earnings Call - Shift to Direct Patient Care Now Majority, But Cash and Covenant Pressure Mounts
Management says 2025 was a year of structural change, with a deliberate pivot from equipment leasing into direct patient care. The shift is real and measurable: direct patient care now generates the m...
- Company completed a strategic shift in 2025 toward a direct patient care model, which now represents the majority of total revenue.
- Total revenue for full-year 2025 was $28.1 million, roughly flat versus $28.3 million in 2024.
- Direct patient care services revenue grew 23.7% to $15.5 million in 2025, while leasing revenue declined to $12.6 million.
- +14 more takeaways
Imunon Q4 2025 Earnings Call - IMNN-001 shows unprecedented phase II OS benefit, OVATION 3 enrolling ahead of plan
Imunon opened the year riding a breakthrough phase II readout for IMNN-001, reporting a final overall survival improvement of 14.7 months in OVATION 2 and an even larger effect in the subgroup receivi...
- Final OVATION 2 phase II overall survival benefit increased to 14.7 months in the company’s final review of the trial.
- Patients who received PARP inhibitor maintenance in OVATION 2 showed a median overall survival improvement of more than two years versus control.
- OVATION 3 is a one-to-one randomized pivotal phase III that mirrors the phase II backbone, testing IMNN-001 plus standard neoadjuvant and adjuvant chemotherapy including interval debulking surgery vs standard of care alone.
- +12 more takeaways
FactSet Q2 FY2026 Earnings Call - ASV Re-acceleration and AI-Driven Data Momentum Lift Guidance
FactSet reported another quarter of re-acceleration, with organic ASV up 6.7% to $2.45 billion and Q2 revenue rising 7.1% to $611 million. Management is arguing that the company is not being displaced...
- Organic ASV accelerated to 6.7% in Q2, reaching $2.45 billion, marking the fourth consecutive quarter of acceleration.
- Q2 revenue grew 7.1% year-over-year to $611 million; adjusted diluted EPS was $4.46, up 4% from a year ago.
- FactSet raised fiscal 2026 ASV guidance to $130 million–$160 million (approx. 5.4%–6.7% growth) and nudged GAAP revenue midpoint up by $25 million.
- +12 more takeaways
BIO-key International FY2025 Earnings Call - Q1 2026 revenue guidance $2.2M, breakeven targeted in 2026
BIO-key closed a soft FY2025 with revenues down 12% to $6.1 million, but management says the softness was largely timing and strategic transition related. A two-year license booked in 2024 and the shi...
- Total FY2025 revenue fell 12% to $6.1 million versus $6.9 million in 2024, with license revenue down materially due to timing and strategic transitions.
- Management guides Q1 2026 revenue of approximately $2.2 million, a 37% increase versus Q1 2025, and says Q1 bottom line will substantially improve versus any quarter in fiscal 2025.
- A two-year license booked in 2024 with a foreign bank depressed 2025 recognized revenue, but that same customer signed an expanded one-year renewal in 2026 worth over $1 million, roughly a 30% increase on the contract.
- +12 more takeaways
Dawson Geophysical Q4 2025 Earnings Call - Single-node upgrade drives utilization and margin recovery
Dawson closed 2025 with a clear operational pivot and measurable financial improvement. The rollout of lightweight single-node channels, combined with higher crew utilization in the U.S. and resumed, ...
- Q4 2025 fee revenues were $22.9 million, up 67% versus Q4 2024.
- Full-year 2025 fee revenues were $61.9 million, a 16% increase versus 2024.
- Q4 2025 produced net income of $0.6 million, or $0.02 per share, reversing a year-earlier quarterly loss.
- +12 more takeaways
SPAR Group, Inc. Q4 & FY 2025 Earnings Call - North America Pivot and ReposiTrak-Powered On-Demand Merchandising
SPAR closed out a transformational 2025, exiting international joint ventures and recentering the business on the U.S. and Canada while rebuilding leadership, systems, and analytics. The transition wa...
- SPAR completed divestiture of international joint ventures and is now focused on the U.S. and Canada as its core markets.
- Fiscal 2025 net revenues were $136.1 million, a 3.3% increase on a comparable U.S. and Canada basis versus 2024.
- U.S. net revenues rose 3.9% to $122.1 million, while Canadian sales were essentially flat at $14.1 million.
- +12 more takeaways
TD SYNNEX Q1 FY2026 Earnings Call - Record billings and EPS as Distribution strength and a turbocharged Hyve drive growth
TD SYNNEX opened fiscal 2026 with a blowout quarter, reporting record non-GAAP gross billings of $25.8 billion, non-GAAP operating income of $590 million, and non-GAAP EPS of $4.73, all well ahead of ...
- Record top-line beat: Non-GAAP gross billings of $25.8 billion, up 24% year over year and above the high end of guidance (20% in constant currency).
- Strong profitability: Non-GAAP operating income $590 million, up 48% year over year; non-GAAP EPS $4.73, up 69% year over year; GAAP EPS $4.04, up 104% year over year.
- New reporting framework: Management will discuss results primarily through two reportable businesses, Distribution and Hyve, to reflect how the company allocates capital and resources.
- +12 more takeaways
Palvella Therapeutics Full Year 2025 Earnings Call - Phase III SELVA win clears path to NDA and potential 2027 approval for QTORIN rapamycin
Palvella used 2025 to stage a classic rare-disease breakout, and the SELVA phase III win in microcystic lymphatic malformations (microLM) is the pivot. Management plans a pre-NDA meeting in Q2 2026, a...
- SELVA phase III in microcystic lymphatic malformations was positive, with highly statistically significant results on the primary Investigator Global Assessment and blinded key secondary MLM MCSS.
- SELVA clinical outcomes: 95% of efficacy-period completers improved, 86% were much or very much improved, and 98% of week-24 completers rolled into the extension study.
- Safety and tolerability in SELVA support chronic use across ages, with 6 discontinuations among 50 phase III enrollees, 5 deemed unrelated and 1 possibly related to study drug.
- +12 more takeaways